Shots:
- The EMA has received MAA of Vizz (1.44% aceclidine ophthalmic solution) for the treatment of presbyopia in adults
- MAA was supported by the 3 P-III (CLARITY) trials evaluating Vizz (QD) across the US, in which Vizz met all 1 & 2EPs, showing rapid near vision improvement within 30min., lasting up to 10hrs.
- Additionally, LENZ plans to pursue commercialization in the EU through strategic partnerships, complementing existing partnerships across Greater China, the Republic of Korea, Southeast Asia, Canada, & the Middle East
Ref: LENZ | Image: LENZ | Press Release
Related News: LENZ Therapeutics’ Vizz Receives the US FDA’s Approval to Treat Presbyopia
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
